Search Results

There are 2856 results for: content related to: Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma

  1. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

    Journal of Cutaneous Pathology

    Volume 41, Issue 6, June 2014, Pages: 539–543, Inbal Braunstein, Tara C. Gangadhar, Rosalie Elenitsas and Emily Y. Chu

    Version of Record online : 11 MAR 2014, DOI: 10.1111/cup.12318

  2. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma

    Journal of Cutaneous Pathology

    Volume 41, Issue 7, July 2014, Pages: 568–575, Kari E. Sufficool, Donna M. Hepper, Gerald P. Linette, Eva A. Hurst, Dongsi Lu, Anne C. Lind and Lynn A. Cornelius

    Version of Record online : 29 APR 2014, DOI: 10.1111/cup.12346

  3. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

    Journal of Cutaneous Pathology

    Volume 40, Issue 7, July 2013, Pages: 667–669, Gene H. Kim, Alan Levy and Goli Compoginis

    Version of Record online : 15 APR 2013, DOI: 10.1111/cup.12149

  4. Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma

    Journal of Cutaneous Pathology

    Volume 40, Issue 10, October 2013, Pages: 884–886, Michael Clarke, Bernhard Ortel, Bruce Brockstein, Theera Rojanapremsuk, Thomas Victor, Antoinette Thomas and Thomas Cibull

    Version of Record online : 7 AUG 2013, DOI: 10.1111/cup.12199

  5. You have free access to this content
    The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S3, April 2014, Pages: 1–15, Michael P Brown and Georgina V Long

    Version of Record online : 8 APR 2014, DOI: 10.1111/ajco.12200

  6. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 987–994, R. Sinha, K. Edmonds, J.A. Newton-Bishop, M.E. Gore, J. Larkin and L. Fearfield

    Version of Record online : 29 OCT 2012, DOI: 10.1111/bjd.12010

  7. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors

    Pigment Cell & Melanoma Research

    Volume 28, Issue 4, July 2015, Pages: 417–430, Casey G. Langdon, Matthew A. Held, James T. Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B. Koo, Michael Klein, Zongzhi Liu, Marcus W. Bosenberg and David F. Stern

    Version of Record online : 6 MAY 2015, DOI: 10.1111/pcmr.12376

  8. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation

    The Journal of Dermatology

    Volume 42, Issue 9, September 2015, Pages: 881–888, Mi Ryung Roh, Jung Min Kim, Sang Hee Lee, Hong Sun Jang, Kyu Hyun Park, Kee Yang Chung and Sun Young Rha

    Version of Record online : 5 JUN 2015, DOI: 10.1111/1346-8138.12950

  9. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

    British Journal of Dermatology

    Volume 173, Issue 4, October 2015, Pages: 1024–1031, R. Sinha, J. Larkin, M. Gore and L. Fearfield

    Version of Record online : 11 OCT 2015, DOI: 10.1111/bjd.13958

  10. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

    British Journal of Dermatology

    Volume 171, Issue 6, December 2014, Pages: 1529–1532, C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche and L. Verneuil

    Version of Record online : 9 NOV 2014, DOI: 10.1111/bjd.13300

  11. You have full text access to this OnlineOpen article
    Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

    Cancer Medicine

    Volume 4, Issue 8, August 2015, Pages: 1205–1213, Geoffrey T. Gibney, Geneviève Gauthier, Charles Ayas, Philip Galebach, Eric Q. Wu, Sarang Abhyankar, Carolina Reyes, Annie Guérin and Yeun Mi Yim

    Version of Record online : 20 MAY 2015, DOI: 10.1002/cam4.475

  12. You have full text access to this OnlineOpen article
    Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state

    Molecular Systems Biology

    Volume 13, Issue 1, January 2017, Mohammad Fallahi-Sichani, Verena Becker, Benjamin Izar, Gregory J Baker, Jia-Ren Lin, Sarah A Boswell, Parin Shah, Asaf Rotem, Levi A Garraway and Peter K Sorger

    Version of Record online : 9 JAN 2017, DOI: 10.15252/msb.20166796

  13. Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy

    Journal of Cutaneous Pathology

    Julia Dai, Christian A. Kunder, Emily Y. Chu, Edward F. Chan, Christine L. Egan and Roberto A. Novoa

    Version of Record online : 13 SEP 2017, DOI: 10.1111/cup.13024

  14. BRAFi-associated panniculitis – an emerging side effect with a variable histological picture: report of two cases and review of the literature

    Journal of Cutaneous Pathology

    Volume 44, Issue 3, March 2017, Pages: 307–309, Joana Ferreira, Helena Toda-Brito, Maria C. Moura, Maria Fernanda Sachse and Joaninha Costa-Rosa

    Version of Record online : 15 DEC 2016, DOI: 10.1111/cup.12857

  15. You have full text access to this OnlineOpen article
    A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

    Pharmacology Research & Perspectives

    Volume 3, Issue 2, March 2015, Simone M. Goldinger, Jeannine Rinderknecht, Reinhard Dummer, Felix Pierre Kuhn, Kuo-Hsiung Yang, Lucy Lee, Ruben C. Ayala, Jagdish Racha, Wanping Geng, David Moore, Mei Liu, Andrew K. Joe, Selby Patricia Gil Bazan and Joseph F. Grippo

    Version of Record online : 2 FEB 2015, DOI: 10.1002/prp2.113

  16. Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

    Pigment Cell & Melanoma Research

    Volume 28, Issue 3, May 2015, Pages: 318–323, Marlous Hoogstraat, Christa G. Gadellaa-van Hooijdonk, Inge Ubink, Nicolle J. M. Besselink, Mark Pieterse, Wouter Veldhuis, Marijn van Stralen, Eelco F. J. Meijer, Stefan M. Willems, Michael A. Hadders, Thomas Kuilman, Oscar Krijgsman, Daniel S. Peeper, Marco J. Koudijs, Edwin Cuppen, Emile E. Voest and Martijn P. Lolkema

    Version of Record online : 7 JAN 2015, DOI: 10.1111/pcmr.12347

  17. Case of vemurafenib-induced Sweet's syndrome

    The Journal of Dermatology

    Volume 41, Issue 9, September 2014, Pages: 817–820, Jeffrey T. Yorio, Steven R. Mays, Ana M. Ciurea, Philip R. Cohen, Wei-Lien Wang, Wen-Jen Hwu, Nydia Gonzalez, Jessica L. Richard and Kevin B. Kim

    Version of Record online : 12 MAR 2014, DOI: 10.1111/1346-8138.12430

  18. Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib

    Pediatric Blood & Cancer

    Volume 63, Issue 3, March 2016, Pages: 541–543, Dolly Aguilera, Anna Janss, Claire Mazewski, Robert Craig Castellino, Matthew Schniederjan, Laura Hayes, Barunashish Brahma, Lauren Fogelgren and Tobey J. MacDonald

    Version of Record online : 18 NOV 2015, DOI: 10.1002/pbc.25787

  19. Profile of vemurafenib-induced severe skin toxicities

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue 2, February 2016, Pages: 250–257, L. Peuvrel, G. Quéreux, M. Saint-Jean, A. Brocard, J.M. Nguyen, A. Khammari, A.C. Knol, E. Varey and B. Dréno

    Version of Record online : 2 NOV 2015, DOI: 10.1111/jdv.13443

  20. You have full text access to this OnlineOpen article
    Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAFV600 mutations

    The Journal of Dermatology

    Volume 42, Issue 7, July 2015, Pages: 661–666, Naoya Yamazaki, Yoshio Kiyohara, Naofumi Sugaya and Hisashi Uhara

    Version of Record online : 17 APR 2015, DOI: 10.1111/1346-8138.12873